These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30204236)

  • 1. Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy.
    Euteneuer JC; Kamatkar S; Fukuda T; Vinks AA; Akinbi HT
    J Clin Pharmacol; 2019 Feb; 59(2):168-176. PubMed ID: 30204236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations.
    Tu Q; Cotta M; Raman S; Graham N; Schlapbach L; Roberts JA
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1383-1399. PubMed ID: 34313180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.
    Samardzic J; Allegaert K; Wilbaux M; Pfister M; van den Anker JN
    Expert Opin Drug Metab Toxicol; 2016; 12(4):367-75. PubMed ID: 26817821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.
    Wang J; Avant D; Green D; Seo S; Fisher J; Mulberg AE; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):328-35. PubMed ID: 25975723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle.
    Allegaert K; Flint R; Smits A
    Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):735-749. PubMed ID: 31402708
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic Drug Monitoring in Neonates: What Makes them Unique?
    Mian P; Flint RB; Tibboel D; van den Anker JN; Allegaert K; Koch BCP
    Curr Pharm Des; 2017; 23(38):5790-5800. PubMed ID: 28950825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs.
    Van den Anker JN; McCune S; Annaert P; Baer GR; Mulugeta Y; Abdelrahman R; Wu K; Krudys KM; Fisher J; Slikker W; Chen C; Burckart GJ; Allegaert K
    Pharmaceutics; 2020 Jul; 12(7):. PubMed ID: 32698409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Hemodynamic and Cerebral Monitoring to Study Pharmacodynamics in Neonates.
    Smits A; Thewissen L; Dereymaeker A; Dempsey E; Caicedo A; Naulaers G
    Curr Pharm Des; 2017; 23(38):5955-5963. PubMed ID: 28925890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for implementation of vancomycin Bayesian software monitoring in a level IV NICU population within a multisite health system.
    Oliver MB; Boeser KD; Carlson MK; Hansen LA
    Am J Health Syst Pharm; 2023 May; 80(11):670-677. PubMed ID: 36860169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
    Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
    Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.
    Kendrick JG; Carr RR; Ensom MH
    Clin Ther; 2015 Sep; 37(9):1897-923. PubMed ID: 26361823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach.
    Frymoyer A; Stockmann C; Hersh AL; Goswami S; Keizer RJ
    J Pediatric Infect Dis Soc; 2019 May; 8(2):97-104. PubMed ID: 29294072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.
    Zhao W; Le Guellec C; Benjamin DK; Hope WW; Bourgeois T; Watt KM; van den Anker JN; Matrot B; Saxen H; Hoppu K; Manzoni P; Jacqz-Aigrain E
    Clin Pharmacokinet; 2014 Nov; 53(11):1005-18. PubMed ID: 25154507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles of therapeutic drug monitoring.
    Zhao W; Jacqz-Aigrain E
    Handb Exp Pharmacol; 2011; 205():77-90. PubMed ID: 21882106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia.
    Cristea S; Smits A; Kulo A; Knibbe CAJ; van Weissenbruch M; Krekels EHJ; Allegaert K
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations for Drug Dosing in Premature Infants.
    van den Anker J; Allegaert K
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S141-S151. PubMed ID: 34185893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates.
    Pons G; Tréluyer JM; Dimet J; Merlé Y
    Ther Drug Monit; 2002 Feb; 24(1):9-14. PubMed ID: 11805715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring--the appropriate use of drug level measurement in the care of the neonate.
    Young TE
    Clin Perinatol; 2012 Mar; 39(1):25-31. PubMed ID: 22341534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalised dosing of medicines for children.
    Al-Metwali B; Mulla H
    J Pharm Pharmacol; 2017 May; 69(5):514-524. PubMed ID: 28266713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling.
    Passot C; Pouw MF; Mulleman D; Bejan-Angoulvant T; Paintaud G; Dreesen E; Ternant D
    Ther Drug Monit; 2017 Aug; 39(4):322-326. PubMed ID: 28703717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.